Blenrep

News

ASCO: DREAMM-8 data puts GSK’s Blenrep back on track

GSK is increasingly confident that its anti-BCMA drug Blenrep could be returned to the US market, after revealing data from the DREAMM-8 trial of the drug in multiple myel

News

GSK scores again with Blenrep in multiple myeloma

GSK continues to build the case for its multiple myeloma therapy Blenrep, which was pulled from the US market last year, with another positive phase 3 trial.

News

GSK backs up its Blenrep rehab bid with survival data

GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there, but was withdrawn from sale after it fail

News

Is GSK’s Blenrep heading for a renaissance?

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the

News

GSK will pull Blenrep from US market after failed trial

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US

News

GSK's Blenrep hopes take a knock as drug fails trial

GSK has great expectations for its BCMA-directed cancer drug Blenrep, but a failed phase 3 trial in relapsed or refractory multiple myeloma has raised doubts about its prospects – and even

ASCO: DREAMM-8 data puts GSK’s Blenrep back on track

GSK scores again with Blenrep in multiple myeloma

GSK backs up its Blenrep rehab bid with survival data

Is GSK’s Blenrep heading for a renaissance?

GSK will pull Blenrep from US market after failed trial

GSK's Blenrep hopes take a knock as drug fails trial

Gilead claims first FDA nod for a hepatitis D therapy

Discover a new era of healthcare panel engagement: Grounded ...

Blenrep

Editor's Picks